NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

From the article you linked,

"The trials will collectively enroll up to 20,000 patients with all stages of cancer. In what was hailed as a first in the U.S., patients participating in the program will be guaranteed access to coverage of next-generation whole genome sequencing and proteomic diagnostics designed to match them to the appropriate therapeutic regimen from day one of their treatment."

That's progress! Bravooooooo!

Even if it brings up some very difficult questions about how to construct proper blinded trials if this practice becomes common even for people in trials.

Does that mean DCVax-L will not become a base treatment for all GBM and possibly all gliomas if such analysis becomes common before clinical trials? I don't know. Could be. Or maybe such analysis would just be used to determine what further adjuncts would be appropriate.

What is the efficacy demonstrated so far for DCVax-L outside of the mesenchymal subgroup? The long tail is all mesenchymal, but for those that do not get 5+ years OS there is still efficacy... how much?